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Abstract
Background: Osteoarthritis (OA) is a common cause of pain and disability. Currently available analgesics are often
insufficiently effective or have unacceptable adverse effects. Tricyclic antidepressants may offer a useful centrally-acting
analgesic. Nortriptyline is a readily-available, cheap and comparatively well-tolerated tricyclic antidepressant.
Methods/Design: We will conduct a parallel group, two-arm, participant and investigator-blinded, randomised
controlled superiority trial comparing nortriptyline with placebo. Two hundred participants with primary knee OA will be
enrolled. Participants will take study medication for 14 weeks. The primary outcome is difference between treatment arms
in mean pain score measured on the Western Ontario and McMaster Universities (WOMAC) pain scale at 14 weeks.
Discussion: This protocol describes the first randomised controlled trial of a tricyclic antidepressant in the treatment of
OA. The results of the study may have significant implications for the management of this common and painful
condition.
Trial registration: The trial was registered with the Australian New Zealand Clinical Trials Registry on 27 June 2014. The
trial registration number is: ACTRN12614000683639.
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Background
Osteoarthritis (OA) is the most common joint disease
and is a major cause of joint pain and disability [1, 2]. In
high-income countries, OA is the fifth leading cause of
years lost to disease, [3] and in New Zealand 15 % of
55–64 year-olds and 26 % of 65–74 year-olds have OA
[4]. The burden of disease and its associated costs are
predicted to rise as the population ages [5]. OA is char-
acterised by pain and loss of function and typically affects
the weight-bearing joints of the lower limbs (hip, knee) as
well as the hand and spine, but it can affect any joint. OA
affecting the knee carries the greatest public health burden
[6]. The major pathological features of the disease are deg-
radation of articular cartilage and adjacent bone remodel-
ling. OA is categorised as either primary or secondary:
primary OA has no known trigger whereas secondary OA
occurs as the result of joint damage from mechanical dam-
age (e.g. fracture), inflammation (e.g. gout and rheumatoid
arthritis) or infection. Risk factors for primary OA include
advancing age, female sex, and obesity.
OA is predominantly managed in primary care. There
is no cure and management is focused on relief of pain
and maintenance of function. A range of interventions is
available according to the severity of the condition. Ini-
tial management consists of patient education, exercise
and weight loss, but many patients will also require anal-
gesics [7]. First-line analgesic choices are typically para-
cetamol and topical non-steroidal anti-inflammatory
drugs (NSAIDs); these may be followed by oral NSAIDs
or weak opioids [7]. None of these analgesics is ideal:
paracetamol, although safe and well-tolerated, may be
no more effective than placebo [8, 9]. NSAIDs are effect-
ive in reducing pain, [9] but they are nephrotoxic, sig-
nificantly increase the risk of gastrointestinal ulceration
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and bleeding, and are associated with cardiovascular
events [10]. The long-term use of NSAIDs is, therefore,
contraindicated in many patients. Opioids are also used
despite poor evidence of their efficacy, and their use is
limited by side effects [11]. Ultimately, OA may be
treated with joint replacement, but access to this inter-
vention is limited by resource constraints, [12] and pa-
tient co-morbidity, and for younger patients delayed
joint replacement is desirable due to prostheses’ limited
life-spans. Hence, there is a need for more effective and
better tolerated pain management for patients with OA.
Central processing of pain in OA
Pain in OA has historically been attributed to the local
nociceptive effects of degeneration of cartilage at the af-
fected joint. Functional imaging has recently revealed areas
of the brain that are involved in central processing of pain
in OA. Functional magnetic resonance imaging (fMRI) has
been used to investigate the central response to painful
mechanical stimulation of osteoarthritic knees, and has
shown an increase in central activation in brain regions as-
sociated with pain [13]. Subsequent treatment of the knee
pain with topical lignocaine reduces central activity [13].
fMRI studies of patients with hip OA have also revealed
greater central activation amongst those patients with
higher levels of neuropathic pain [14]. The central effects
of OA pain have also been explored using positron emis-
sion tomography (PET) and a similar increase in activity in
pain-processing centres in participants with OA pain com-
pared to those without pain has been demonstrated [15].
Antidepressants as a novel pain treatment in OA
The discovery of central pain-processing activity in OA has
suggested a potential new therapeutic approach for pain
control in OA [16]. Recent trials of the serotonin and nor-
adrenalin reuptake inhibitors (SNRIs) venlafaxine [17] and
duloxetine [18–20] have shown statistically and clinically
significant reductions in pain in patients with OA. The
study of venlafaxine, however, was very small (n = 18) and
used a single-blind, placebo run-in design rather than a
randomised controlled trial (RCT). The duloxetine studies
were larger (n = 256 to n = 524), were double-blind RCTs,
and demonstrated significantly greater reduction in pain
and greater improvement in physical functioning with
duloxetine than with placebo; however, duloxetine was
also associated with significantly more side effects and
higher rates of discontinuation than placebo. Furthermore,
whilst duloxetine is licensed in New Zealand, it is not sub-
sidised so is not readily available to many of our patients.
Tricyclic antidepressants (TCAs), which are
pharmacologically-related to the SNRIs, are commonly
used in other chronic pain conditions: for example, in back
pain and fibromyalgia, [21–23] but their potential benefits
in treating OA pain have not yet been tested in a well-
designed RCT. A very small (n = 24) cross-over study of im-
ipramine in 1969 suggested a reduction in OA pain [24].
However, this study had several limitations in addition to its
small size: the study population was mixed and only 7 par-
ticipants had OA (other participants had rheumatoid arth-
ritis and ankylosing spondylitis), the treatment periods were
short (3 weeks), and there was no washout period between
treatment periods. Furthermore, imipramine has a high rate
of adverse effects [25]. Nortriptyline is a better-tolerated
TCA and is readily available at low cost. TCAs have a range
of adverse effects, particularly dry mouth, constipation and
drowsiness but nortriptyline is amongst the best tolerated
[25, 26]. If nortriptyline proves to have a useful analgesic ef-
fect and a tolerable side effect burden it will be a valuable
addition to the analgesic options for patients with OA.
Study aim
To measure the effectiveness, safety and tolerability of
nortriptyline compared to placebo in reducing pain and
improving function in patients with knee OA.
Hypotheses
In patients with knee OA, a 14-week course of nortripty-
line delivered in addition to usual care will lead to:
1. A significant reduction in OA pain compared to
placebo.
2. A significant improvement in physical function
greater than with placebo.
Methods/Design
We propose a parallel group, two-arm, participant and
investigator-blinded, randomised controlled superiority
trial comparing nortriptyline with placebo.
The study population consists of adult patients living in
the Canterbury region of New Zealand with primary knee
OA (defined according to American College of Rheumatol-
ogy (ACR) criteria) causing moderate to severe pain [27].
The ACR clinical criteria will be used as these require clin-
ical findings without x-ray confirmation to confirm the
diagnosis of OA. These criteria have slightly lower specifi-
city than the clinical plus x-ray criteria, but their use more
closely matches current practice and management guide-
lines for primary care management of OA. Recruitment will
be from the Canterbury District Health Board’s (CDHB’s)
orthopaedic service, from primary care, and from public
advertisements.
Inclusion criteria
1. Primary knee OA defined according to ACR
classification criteria (knee pain plus 3 of: age > 50
years, morning stiffness lasting < 30 minutes,
crepitus, bony tenderness, no palpable warmth) [27].
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2. Pain severity of ≥ 20 points on the Western Ontario
and McMaster Universities (WOMAC) numerical
rating scale (range 0 to 50 points) at the study
knee [28].
3. Stable analgesic regime for 2 months before entering
the study.
Exclusion criteria
1. Prior joint replacement surgery on the study knee
2. Intra-articular steroid injection within the previous
3 months
3. Secondary OA (OA due to inflammatory arthritis
(e.g. gout, rheumatoid arthritis, juvenile arthritis),
septic arthritis or trauma (articular fracture))
4. Known hypersensitivity to nortriptyline or history of
adverse reaction to any TCA
5. Current use of nortriptyline or other
antidepressants, amiodarone or domperidone





10. Hyperthyroidism or phaeochromocytoma under
current investigation or treatment
11. History of epilepsy or other seizure
12. History of bipolar disorder or manic episode





Potential participants will be identified from the CDHB
orthopaedic department and from local general practi-
tioners’ (GPs’) enrolled patient lists. Patients identified
from the orthopaedic department will have been assessed
as being below threshold for operative treatment for OA.
Public advertising will be undertaken in venues typically
frequented by older adults: for example, bowling clubs
and social clubs. To optimise involvement of Indigenous
New Zealanders (Māori), recruitment will be undertaken
in marae (Māori meeting place) and through the Māori
health arm of Ngai Tahu, the principal iwi (tribe) in the
South Island of New Zealand.
Potential participants identified through these avenues
will be sent a letter outlining the study. The letter will in-
clude a postage-paid response card which those interested
in taking part in the study can return to the research sec-
retary. Individuals indicating willingness to participate will
be phoned by the research nurse who will conduct a brief
eligibility screen and will invite potential participants to
attend a full screening assessment.
Screening assessment
A screening assessment will be conducted by the re-
search nurse to ensure potential participants meet the
inclusion and exclusion criteria. Potential participants’
GPs will be asked to confirm whether there any contra-
indications to the use of nortriptyline.
The study Clinical Review Team will decide each po-
tential participant’s eligibility for the study. Once eligibil-
ity has been confirmed a baseline assessment will be
undertaken. Participants will be asked to record NSAID
and other analgesic use for 2 weeks before their baseline
assessment.
Baseline assessment, informed consent and assignment
of intervention
At the baseline assessment appointment the research
nurse will further explain the study, answer any questions
and seek informed consent. All participants will provide
written informed consent to their participation in the
study and will then be assigned a unique sequentially-
numbered study identifier according to the order in which
he or she is enrolled in the trial. The participant will then
complete the baseline assessment and anthropometric
measures before the research nurse dispenses the study
medication.
Sequence generation
Participants will be randomly divided into two groups
(A and B) of equal size using a computer-generated ran-
domisation schedule with permuted blocks of random
size prepared by the study statistician. The randomisa-
tion schedule will not be stratified as the risk of import-
ant imbalances in prognostic factors is small for a trial
of this size [29].
Allocation concealment and implementation
The study medication (nortriptyline or identical placebo)
will be packaged in identical containers. Each container will
be pre-labelled (by the study pharmacist contracted to pro-
vide the study medication) with a study identifier according
to randomisation schedule. The contracted pharmacist will
determine which group of participants, A or B, will be allo-
cated to receive nortriptyline. Neither the study statistician
nor the contracted pharmacist will have any contact with
the participants, nor will they be able to influence treatment
allocation. Study numbers and study medication will be is-
sued sequentially to participants.
Blinding
The study investigators, the research nurse dispensing the
medication and assessing outcomes, and the participants
will remain blind to the treatment allocation. After the
final assessment, the participant’s study arm allocation will
be un-blinded and this information will be communicated
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to the participant’s GP, thus allowing for continued pre-
scription (if desired) of the active medication for those
participants in the active treatment arm. The task of un-
blinding will be performed independently by a member of
the host department staff who is not involved with the
study, and allocation will not be revealed to the research
nurse or any of the investigators. We will assess the effect-
iveness of the allocation blinding by asking participants
and the research nurse at the final assessment which arm
of the study they believe the participant had been allo-
cated to. To prevent accidental un-blinding there will be
no contact between the study team and the participant
until after data cleaning, database lockdown and analysis
are complete.
Study medication
Nortriptyline dosing has high inter-individual variability:
the effective and tolerated daily dose ranges from < 25 mg
to > 100 mg [30, 31]. To allow for this, participants will
pass through an 8-week blinded dose-adjustment period
to allow titration of study medication according to anal-
gesic effect and tolerability. This process closely resembles
usual clinical practice when initiating a TCA.
Dose-adjustment period (weeks 0–8)
All participants will receive capsules containing nortrip-
tyline 25 mg or identical placebo capsules and will be
instructed to start study medication at a dose of 1 cap-
sule at night. Every 2 weeks the research nurse will tele-
phone participants and record their response to the
study drug: participants will be asked whether they have
experienced any change in their knee pain and whether
they have experienced adverse effects. Participants who
have achieved satisfactory pain relief will be instructed
to continue their current dose. If pain relief is inad-
equate and side effects are tolerated then the participant
will be instructed to increase their daily dose by one
capsule. If side effects are intolerable then the daily dose
will be reduced by one capsule. Dose adjustment will be
carried out over 8 weeks to allow participants to reach
the potential maximum dose of 4 capsules daily of study
medication (a potential maximum dose of 100 mg nor-
triptyline daily) if required and tolerated. At each of
these telephone reviews adverse events will be recorded
and serious adverse events (SAEs) will be immediately
notified to the Clinical Review Team.
Steady dose treatment period (weeks 8–14)
Following the initial dose-adjustment period, participants
will continue at their maximum tolerated or effective dose
for 6 weeks, a period consistent with published recom-
mendations on OA research [32]. During this period par-
ticipants will not be routinely contacted but they will be
encouraged to contact the research nurse by phone if they
have questions relating to their study medication.
Participants will be free to use their usual pain reliev-
ing medication as prescribed by their GP during the
study period. Participants’ GPs will be informed of their
patients’ participation in the study and will be asked not
to prescribe nortriptyline or any other antidepressants to
participants during the study period.
Outcome measures
In line with recommended practice in OA trials, we will
assess outcomes in the domains of pain, physical func-
tion and participant global assessment [33].
Primary outcome
Difference between treatment arms in mean pain score
at 14 weeks, measured using the WOMAC pain subscale
and adjusted for pain score at baseline.
Secondary outcomes
The following outcomes will be assessed at 14 weeks in
a structured interview:
1. Physical function using the WOMAC function
subscale
2. Participant-rated global assessment using a visual
analogue scale (VAS)
3. Difference in the proportion of participants
reporting a treatment effect, defined according to
the Osteoarthritis Research Society International
(OARSI) set of responder criteria [34]
4. Quality of life using the 36-Item Short-Form Health
Survey 36 (SF36) survey
5. Participant-recorded NSAID and other analgesic use
in the final 2 weeks of the study period
6. Adverse events will be coded using the Common
Terminology Criteria for Adverse Events (CTCAE)
[35]. Tricyclic adverse effects will be recorded
using the Antidepressant Side-Effect Checklist,
[36] measured at 14 weeks.
The WOMAC knee OA index measures the three do-
mains of pain, disability and joint stiffness using a set of
24 questions. It is amongst the most widely used mea-
sures of lower limb symptoms and has been well-
established as a valid, reliable and responsive measure of
pain and disability in OA [37, 38]. The WOMAC index
used in this study will be version 3.1 in the 11-point nu-
merical rating scale format standardised in English for a
New Zealand population. The pain component of the
WOMAC index covers five situations: walking on a flat
surface, going up or down stairs, night pain, sitting or
lying, and standing. The level of pain experienced in each
of the 5 situations is scored from 0 to 10 (no pain to
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extreme pain) to give a combined maximum score of 50.
Minimal training is required to administer the WOMAC,
and completion time is approximately 12 minutes per
participant.
Baseline assessment measurements
In addition to the primary and secondary outcome mea-
sures, the research nurse will also record participants’:
1. Age
2. Sex
3. Ethnicity (using New Zealand Census 2006
categories)
4. Height and weight for calculation of body mass
index (BMI)
5. Study knee disease duration
6. Location and number of other osteoarthritic joints
7. Use of assistive devices
8. Current medication use:
a. Analgesics (including NSAIDs)
b. All other medications
9. Other chronic conditions.
Final assessment
The research nurse will assess each participant at the
study clinic at week 14. The following data will be
recorded:
1. Pain using the WOMAC pain scale
2. Physical function using the WOMAC function scale
3. Participant-rated global assessment using a VAS
4. Quality of life using the SF36 survey
5. NSAID and other analgesic use in the previous 2
weeks
6. Tricyclic adverse effects using the Antidepressant
Side-Effect Checklist
7. Other adverse events
8. Participant’s belief about treatment arm allocation
Study medication withdrawal
Withdrawal of TCAs (including nortriptyline) may be as-
sociated with antidepressant discontinuation symptoms. It
is, therefore, recommended that these medications are
withdrawn in a gradual fashion rather than stopping
abruptly. We will recommend a tapered withdrawal to
participants in the active arm of the study at the comple-
tion of the study. The daily dose will be reduced by 1 cap-
sule (25 mg nortriptyline) every week. To ensure that the
investigators and the research nurse remain blinded, this
information will be communicated to the participant in a
pre-prepared letter which will be posted to the participant
by a non-blinded member of the host department. Partici-
pants in the placebo arm will also receive a pre-prepared
letter informing them of their treatment allocation and
that they can simply stop taking their study medication.
Sample size
The minimum important clinical difference for a reduc-
tion in pain measured using the WOMAC osteoarthritis
index has been determined to be about 10 % of the scale
maximum, or a total difference of 5 points on the
WOMAC pain numerical rating scale (range 0 to 50)
[39]. A sample size of 85 per group will give at least 90 %
power at a 2-sided significance level of 0.05 to detect a dif-
ference in treatment effect of 5 points between the nor-
triptyline and placebo groups. The sample size was
calculated using a pooled standard deviation 10 points es-
timated from previous studies, [40] and conservatively as-
suming no correlation between baseline and follow-up
scores. This sample size also allows for detection of the
minimum important clinical difference in the proportion
of participants responding to treatment according to the
Outcome Measures in Rheumatology-OARSI (OMER-
ACT-OARSI) criteria [34]. The sample size will be inflated
to 100 participants per group (200 in total) to account for
a possible 15 % loss-to-follow-up.
Data management and statistical analysis
Participants’ data will be recorded in individual participant
record booklets. Data will be entered into an Access data-
base (Microsoft, Redmond, WA, USA) and then exported
to the latest available versions of R and Stata (StataCorp,
College Station, TX, USA) [41].
Data analysis will be performed on an intention-to-
treat basis with primary and secondary outcomes com-
pared between participants randomised to nortriptyline
versus those randomised to placebo regardless of adher-
ence to entry criteria, study medication actually taken,
treatment withdrawal, or protocol deviation. A per-
protocol analysis will also be performed. Unit of analysis
will be at the level of the patient, where patients with OA
in both knees will choose the most symptomatic to be the
one under study. No interim analyses will be undertaken.
All statistical tests will be 2-sided and a level of signifi-
cance (alpha) of ≤ 0.05 set for all confidence intervals and
p values. Demographic characteristics and baseline data
will be summarised using descriptive statistics, and pre-
sented by treatment group. The mean and standard devi-
ation of participants’ WOMAC pain score at 14 weeks
follow-up, and change between baseline and 14 weeks, will
be calculated for each treatment group.
The primary outcome of the study will be the size of the
treatment effect (mean difference in pain between treat-
ment groups at 14 weeks adjusting for differences at base-
line), which will be determined using linear regression
modelling including treatment group as fixed effect and
baseline pain scores as a covariate. A secondary analysis of
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this primary outcome will be conducted using multivariable
linear regression, adjusting for pre-randomisation variables
reasonably expected to predict a favourable outcome
(duration of disease, medication use at baseline, and
use of assistive devices), and participants’ use of other
analgesics (paracetamol, NSAIDs, and opioids) in the 2
final weeks of the study period (weeks 12–14). Second-
ary continuous outcome measures (WOMAC function
and stiffness, patient global assessment, and quality of
life measures) will be analysed in a similar manner.
As secondary analysis, patients will be dichotomised
according to the OMERACT-OARSI set of responder
criteria, defined as a high improvement in pain or func-
tion, or a moderate improvement in at least two of pain,
function, or patient’s global assessment [34]. Incident
rates will be calculated for this and other binary out-
comes (including use of other pain medications, adverse
events, and tricyclic side effects) and compared using
chi-square or Fisher exact tests. Generalised linear re-
gression models will be used to calculate absolute and
relative differences in risk between treatment groups
with 95 % confidence intervals, adjusting for other vari-
ables as appropriate. Self-reported treatment dosage over
the past 2 weeks will be summarised for each follow-up,
as will the number of participants discontinuing treat-
ment and reasons for doing so. The incidence of all sus-
pect serious treatment reactions will be presented in line
with the CONSORT 2010 recommendations [42].
Participants who are missing outcome data will be in-
cluded in the analysis using modern multiple imputation
methods. To determine the robustness of results per
protocol analysis will be performed, excluding participants
with major protocol violations such as cross-over treat-
ments, withdrawals and loss-to-follow-up. Dose-response
will be investigated by entering final dose achieved as a
predictor in regression models.
Ethical approval
The study was approved by the Northern A Health and
Disability Ethics Committee. Ethics ref 14/NTA/139.
Discussion
This protocol outlines the design of the first randomised
controlled trial of a TCA in the management of OA. As
there is currently a paucity of effective and safe analgesics
for this common condition, the results of the study may
have widespread clinical and public health implications.
Trial status
The trial was registered with the Australian New Zealand
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Criteria for Adverse Events; GP: general practitioner; fMRI: functional
magnetic resonance imaging; NSAID: non-steroidal anti-inflammatory drug;
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tomography; RCT: randomised controlled trial; SAEs: serious adverse events;
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